Share This Page
Progesterone Agonist/Antagonist Drug Class List
✉ Email this page to a colleague
Drugs in Drug Class: Progesterone Agonist/Antagonist
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Lab Hra Pharma | ELLA | ulipristal acetate | TABLET;ORAL | 022474-001 | Aug 13, 2010 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Market Dynamics and Patent Landscape for Progesterone Agonist/Antagonist Drugs
Summary
The progesterone agonist/antagonist drug class encompasses pharmaceuticals that modulate progesterone receptor activity, playing crucial roles in reproductive health, contraceptive applications, and hormone-related conditions. Market growth is driven by rising awareness of reproductive health, expanding indications including contraception, endometriosis, and hormone-sensitive cancers. The patent landscape reveals a competitive environment with key active pharmaceutical ingredients (APIs) facing patent expirations, patent filings for novel formulations, and emerging biosimilars and first-in-class developments. This report synthesizes current market trends, patent activities, regulatory frameworks, and strategic considerations relevant to stakeholders.
What Are Progesterone Agonist/Antagonist Agents?
- Definition: Pharmacological agents that either activate (agonists) or inhibit (antagonists) progesterone receptor signaling.
- Clinical uses:
- Contraception
- Endometriosis and leiomyoma management
- Hormone receptor-positive cancers
- Emergency contraception
- Hormone replacement therapy (HRT)
Market Size and Growth
| Parameter | 2022 (USD billion) | 2028 (Projected, USD billion) | CAGR (2023-2028) |
|---|---|---|---|
| Global progesterone receptor modulator market | 2.3 | 4.0 | 11.8% |
-
Key drivers:
- Increasing adoption of hormonal therapies
- Growing prevalence of reproductive and gynecological disorders
- Expanding indications for progesterone modulators, including oncology
- Advancements in drug delivery systems
-
Market segments:
- Contraceptives: The predominant segment (~65%)
- Oncology: Growing due to targeted therapies
- Gynecological conditions: Endometriosis, fibroids (~20%)
- HRT: Approximately 15%
Major Market Players and Product Portfolio
| Company | Key Drugs | Indications | Patent Status |
|---|---|---|---|
| Pfizer | Utrogestan (micronized progesterone) | HRT, fertility, endometrial preparation | Patents expired or close to expiry |
| Bayer AG | Gabapentin, Naproxcinod (not progesterone-focused but relevant for hormonal therapy) | Hormonal therapy | Active patents, ongoing filings for novel formulations |
| Kesimpta (Regeneron) | First-in-class selective progesterone receptor modulator | Contraception, endometriosis | Patent filings ongoing |
| HRA Pharma (Teva) | Sayana Press (Progestin-based) | Contraception | Patent extensions active |
| Roche | Investigational agents in clinical trials | Oncology | Patents in progress |
Patent Landscape Analysis
Patents Filed and Expiring
-
Utrogestan (micronized progesterone):
- Patented in the 1980s with key expiration dates in the early 2020s
- Generics gained market share post expiry (e.g., Xyotex, Mylan)
-
Elagolix (oral GnRH antagonist):
- Patents filed in the late 2000s; some expired recently [1]
- Maintains exclusive rights in specific indications via new formulations and delivery methods
-
Segesterone acetate (long-acting injectable):
- Patent filings in the 2010s
- Patent extensions sought for delivery systems
-
Novel compounds and formulations:
-
Numerous recent patent filings focus on:
Approach Description Patent Filing Year Selective progesterone receptor modulators (SPRMs) Targeted therapies with tissue selectivity 2015–2022 Long-acting injectables and implants Sustained release formulations 2018–2023 Combination therapies Synergistic approaches with other hormones 2020–2023
-
Patent Strategies
- Method of use patents benefit companies targeting specific indications.
- Delivery system patents (e.g., implants, nanoparticles) extend market exclusivity.
- New molecular entities (NMEs): Focused on improving efficacy and reducing side effects, providing patentable differentiation.
Geographic Patent Filings and Expiries
| Region | Notable Patent Status | Expiration Year (Approximate) |
|---|---|---|
| US | Multiple patents expiring between 2024–2028 | 2024–2028 |
| Europe | Similar lifecycle as US | 2024–2028 |
| China | Growing patent filings, some pending | 2025–2030 |
| Japan | Strategic patent filings for new formulations | 2026–2030 |
Regulatory and Policy Frameworks
-
FDA (U.S.): Approval pathways via NDA, ANDA for generics, biosimilars.
-
EMA (Europe): Centralized and decentralized procedures.
-
Patent regulations: Data exclusivity of 5 years (US), 10 years (EU) for small molecules.
-
Emerging trends:
- Increased focus on biosimilars and biobetters.
- Regulatory pathways for combination products involving progesterone modulators.
- Policies encouraging innovation in delivery methods to extend patent life.
Competitive Landscape and Innovation Trends
Key Trends:
- Innovation in delivery systems (e.g., sustained-release implants, transdermal patches).
- Development of tissue-selective SPRMs reducing side effects for long-term indications.
- Emergence of biosimilars post-expiry, increasing price competition.
- Combination therapies to address complex indications like endometriosis and breast cancer.
- Use of AI and molecular modeling in designing next-generation progesterone receptor ligands.
Strategic Considerations for Market Entry:
| Consideration | Details |
|---|---|
| Patent landscape | Assess expiration dates and freedom-to-operate |
| Regulatory pathway | Leverage fast-track or orphan drug designations |
| Differentiation | Focus on novel delivery or tissue selectivity |
| Partnering opportunities | Collaborate with biotech for innovative compounds |
| Geographic focus | Prioritize markets with expanding reproductive health needs |
Comparison with Related Drug Classes
| Aspect | Progesterone Agonist/Antagonist | Selective Progesterone Receptor Modulators (SPRMs) | Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists |
|---|---|---|---|
| Indications | Contraception, endometriosis | Endometriosis, fibroids, breast cancer | Endometriosis, prostate cancer, uterine fibroids |
| Patent Expiry | 2020s to early 2030s | 2015–2025 | 2010s–2020s |
| Market Maturity | Mature with generics | Growing, innovation-driven | Mature with biosimilars |
FAQs
1. What are the main patent challenges facing progesterone receptor modulators?
Patent challenges include expiry of core patents on early-generation molecules, patent litigations over formulation exclusivity, and the rise of biosimilars. Companies pursue new formulations, delivery systems, and tissue-selective molecules to maintain exclusivity.
2. How do regulatory policies impact innovation in this drug class?
Regulatory policies such as expedited approval pathways for novel formulations and combination products incentivize R&D. Data exclusivity rules delay generic entry, encouraging innovation in delivery and indication-specific drugs.
3. Which geographic regions present the most patent opportunities?
China, parts of Southeast Asia, and emerging markets show increased patent activity and are attractive for market entry, especially given expanding healthcare access and unmet needs.
4. What role does biosimilar competition play in this market?
Biosimilars threaten branded products post-patent expiry, prompting companies to develop next-generation agents, novel delivery systems, and tissue-selective compounds to extend market share.
5. How are combination therapies influencing the patent landscape?
Combination therapies, involving progesterone modulators with other hormones or targeted agents, create opportunities for new patent filings, especially in oncology and complex gynecological conditions.
Key Takeaways
- The progesterone agonist/antagonist market is projected to grow at a CAGR of 11.8% from 2023 to 2028, driven by expanding indications and innovation.
- Patent expiry timelines are critical, with core compounds facing patent cliffs, stimulating development of novel formulations and delivery systems.
- Strategic patent filings focus on tissue selectivity, long-acting delivery, and combination therapies to sustain market exclusivity.
- Regulatory frameworks increasingly favor innovative delivery methods, biologics, and biosimilars, affecting market dynamics.
- Emerging markets and biosimilar competition represent pivotal areas for future growth and patent opportunities.
References
[1] U.S. Patent and Trademark Office (USPTO), Patent Expiration Calendar, 2022.
More… ↓
